智通财经APP获悉，宜明昂科-B(01541)涨超10%，截至发稿，涨10.46%，报5.28港元，成交额703.34万港元。
消息面上，3月17日，宜明昂科宣布，公司自主研发的阿沐瑞芙普α（IMM0306）治疗原发性膜性肾病（Primary Membranous Nephropathy, PMN）的II期临床研究已正式获得国家药品监督管理局（NMPA）批准。这是IMM0306在自身免疫性肾病领域布局的又一重大里程碑，标志着该创新药物向肾病治疗领域迈出实质性的一步。
公司表示，此次IMM0306在治疗原发性膜性肾病（PMN）适应症上的II期临床获批，连同近期阿沐瑞芙普α皮下注射制剂（IMM0306S），是宜明昂科在自身免疫性疾病领域密集布局的最新成果，也是公司“自免管线多点突破”战略的重要体现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.